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Background: The complexity of pain after laparoscopic cholecystectomy (LC) needs multi-module anal-
gesia. Opioids are widely used for perioperative pain but associated with numerous adverse effects. We
investigated the effect of parecoxib administrated preoperatively and postoperatively for analgesia after
ambulatory laparoscopic cholecystectomy.
Methods: 120 patients scheduled for ambulatory LC with general anesthesia were randomly assigned to
three groups: group A received 40 mg parecoxib injection 30e45 min before anesthesia induction and
4 ml saline injection when gallbladder was removed; group B received 4 ml saline injection 30e45 min
before anesthesia induction and 40 mg parecoxib injection when gallbladder was removed; group C
received 4 ml saline injection 30e45 min before anesthesia induction and the time when gallbladder was
removed. We recorded the time achieve to modiﬁed Aldrete’s score > 9 in the post-anesthesia care unit
(PACU) and modiﬁed Post-Anesthetic Discharge Scoring System (PADSS) > 9 in ambulatory unit. The
visual analog scale (VAS) was used to assess the degree of the postoperative pain in the ﬁrst 24 h, and the
numbers of patients who need additional analgesic and postoperative adverse effects were also recorded.
Results: Patients of group A had a shorter length of stay (LOS) in PACU compared to these of group B and
group C (32.4  7.2 min vs. 39.1  10.4 min and 42.2  7.6 min, P < 0.05). Patients of group A also had a
shorter discharge time compared to these of group B and group C (148.4  39.3 min vs. 187.9  47.7 min
and 223.4  52.5 min, P < 0.05). Moreover, patients of group A experienced reduced pain intensity, less
postoperative side effect, and less additional analgesic requirement.
Conclusion: Preoperative administration of parecoxib for postoperative analgesia provided signiﬁcant
effect on reducing PACU length of stay (LOS) and discharge time, and improving patient outcome after
ambulatory LC.
 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Nowadays the patients’ postoperative satisfactionwas improved
mainly by modiﬁed methods and minimally invasive surgery [1,2].
Compared to open cholecystecomy, laparoscopic cholecystectomy
(LC) can reduce postoperative pain and analgesic consumption
[3,4]. Pain make patients feel discomfort, increase the post-
operative morbidity and prolong the LOS in hospital. This is a
crucial issue in many hospitals especially for patients who were
performed ambulatory LC [5]. Though LC is a minimally invasive
surgery, moderate to severe pain after LC are still an existing
problem and may require opioids analgesic treatment [1].engdu, Sichuan, China.
. Xiao).
by Elsevier Ltd. All rights reservedAlthough opioids can reduce effectively postoperative pain, it is
also well known their many side effects, especially in large doses,
such as nausea, vomiting, constipation, syncope, skin itching, uri-
nary retention and even respiratory depression, which make pa-
tients uncomfortable and delay patients recovery, therefore, largely
limit their clinical use on treating postoperative pain [6,7]. Mean-
while, non-steroidal anti-inﬂammatory drugs (NSAIDs) play an
increasingly important role in the postoperative analgesia aim to
reduce opioids consumption and their adverse effects [8,9]. Recent
researches indicated that a selective COX-2 inhibitor NSAIDs could
effectively manage perioperative pain by reducing periphery
inﬂammation, modulating the nociceptors, and attenuating central
sensitization [10,11]. Parecoxib as a pro-drug of valdecoxib, is the
ﬁrst selective COX-2 inhibitor available for intravenous injection.
The onset time of valdecoxib’s analgesic effect is 10 min, the
duration of maximum effect is 2e4 h and the half-life time of this
drug is 6e10 h [12]..
Table 1
Discharge scoring systems.
The Aldrete’s scoring system The Post-Anesthetic Discharge Scoring
System (PADSS)
Respiration
Able to take deep breath and
cough ¼ 2
Dyspnea/shallow breathing ¼ 1
Apnea ¼ 0
Vital signs
BP & pulse within 20% preop ¼ 2
BP & pulse within 20e40% preop ¼ 1
BP & pulse within >40% preop ¼ 0
Oxygen saturation
Maintains >92% on room air ¼ 2
Needs O2 inhalation to maintain O2
saturation >90% ¼ 1
O2 saturation <90% even with
supplemental oxygen ¼ 0
Activity
Steady gait, no dizziness or meets
preop level ¼ 2
Requires assistance ¼ 1
Unable to ambulate ¼ 0
Consciousness
Fully awake ¼ 2
Arousable on calling ¼ 1
Not responding ¼ 0
Nausea and vomiting
Minimal/treated with p.o.
medication ¼ 2
Moderate/treated with parenteral
medication ¼ 1
Severe/continues despite
treatment ¼ 0
Circulation
BP20 mm Hg preop ¼ 2
BP20e50 mm Hg preop ¼ 1
BP50 mm Hg preop ¼ 0
Pain
Controlled with oral analgesics
and acceptable to patient:
Yes ¼ 2, No ¼ 1
Activity
Able to move 4 extremities ¼ 2
Able to move 2 extremities ¼ 1
Able to move 0 extremities ¼ 0
Surgical bleeding
Minimal/no dressing changes ¼ 2
Moderate/up to two dressing
changes required ¼ 1
Severe/more than three dressing
changes required ¼ 0
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ORIGINAL RESEARCHSeveral investigators have proposed that preoperative admin-
ister long-acting analgesic drugs to prophylaxis pain stimulation
can prevent or reduce postoperative pain. Effective prophylaxis
could not only reduce adverse effects during the recovery period
but also prevent harmful stimulation so as to minimize hyperex-
citability in the central nervous system(CNS) [13,14]. Clinically, this
way was proved to reduce early postoperative pain as well as
reduce the intensity of postoperative pain [15,16]. The commonly
used preoperative or preemptive analgesic solutions include: in-
jection opioids or NSAIDs, local anesthetic inﬁltration, nerve block
and epidural anesthesia [17]. For example, preincisional ilioinguinal
and iliohypogastric nerve block in day-surgery patients undergoing
herniorrhaphy under spinal anesthesia could signiﬁcantly decrease
the number of patients who needed analgesics and the amount
required of analgesics [18]. Intravenous opiates or ketamine pre-
emptively administered could reduce postoperative pain and
decrease wound hyperalgesia days after the surgery of elective
hysterectomy [19]. But among these solutions, NSAIDS were most
popularly studied and used.
The aim of our study was to evaluate whether preoperative
administration of parecoxib could successfully reduce PACU LOS and
discharge time, improve patients’ outcome after ambulatory LC.
2. Materials and methods
The study protocol was approved by the Ethics Committee of
West China Hospital, Sichuan University. Written informed consent
was obtained from all patients. Based on a random, prospective,
double blind design and control methods, 120 patients (ASA I -II)
underwent ambulatory LC were randomly assigned into three
groups with forty in each by computer-randomized number, which
generated by professional statisticians. An anesthesiologist who
gave the dugs implemented the blinding protocol and another
anesthesiologist who didn’t know the regimen evaluated the
postoperative indexes.
The exclusion criteria included: age under 18 years old, medical
history of bleeding liability, gastrointestinal ulcer, renal or hepatic
dysfunction, severe cardiovascular disease, and severe hyperten-
sion, allergy to aspirin-like drugs or sulphonamide. Patients con-
verted to open cholecystectomy or instated with drain tube were
also excluded from the study. All the patients received intravenous
anesthesia and mechanical ventilation. When patients arrived in
the operation room, they weremonitored with ECG, NIBP, SpO2 and
PetCO2. Anesthesia was induced with 0.25 mg/kg sufentanil, 0.1 mg/
kg penehydedine hydrochloride, 2 mgmidazolam, 4 mg/ml propofol
by target-controlled-infusion (TCI), and 0.6 mg/kg rocuronium.
Mechanical ventilation was used after intubation. Anesthesia was
maintained with 2.5e3.5 mg/ml propofol by TCI, 0.1e0.2 mg/kg/min
remifentanil and rocuronium. After gallbladder was removed, all
patients received 8 mg ondansetron IV to prevent postoperative
nausea and vomiting and then remifentanil was stopped. Patients
were received additional analgesic when VAS> 4 or patients asking
for analgesic, sufentanil 5e7.5 ug was injected IV in the PACU,
tramadol 100 mg was administrated IM in the ambulatory ward or
discharged. Group A received 40 mg parecoxib injected 30e45 min
before anesthesia induction and 4 ml saline injected when gall-
bladder was removed; group B received 4 ml saline injected 30e
45 min before anesthesia induction and 40 mg parecoxib injected
when gallbladder was removed; group C received 4 ml saline
injected both 30e45 min before anesthesia induction and gall-
bladder was removed. All patients were not given local inﬁltration
at port sites.
Times to modiﬁed Aldrete’s score > 9 and modiﬁed PADSS > 9
and postoperative adverse effects were recorded (Table 1). The
modiﬁed Aldrete’s score was evaluated 10 min postoperatively andthen every 5 min; the PADSS was evaluated 1 h postoperative and
then every half hour. The side effects include: nausea, vomiting,
backache, dizziness, somnolence, agitation and urinary retention.
The intensity of the postoperative pain was valued in the ﬁrst 24 h
at 0 h, 0.5 h,1 h, 2 h, 4 h, 6 h,12 h, 24 h after surgery using a VAS (0e
10, 0 ¼ no pain, 10 ¼ worst possible pain), the number of patients
who needed additional analgesic was also recorded. Agitation was
assessed according to Ramsay Scale (RS): 0, quiet and cooperation;
1, body moved by stimulation such as sputum suction; 2, physical
struggle even has no stimulation, but don’t need paramedics brake;
3, head and body ﬁerce struggle, need many people catch. 0, 1
belong to not have agitation; 2, 3 belongs to have agitation.
The primary outcome was the times to modiﬁed Aldrete’s
score > 9 and modiﬁed PADSS > 9. The modiﬁed PADSS > 9 was
normal distribution and tested by analysis of variance (ANOVA)
(post hoc least-signiﬁcant difference); the modiﬁed Aldrete’s
score> 9was non-normal distribution and tested by KruskaleWills
H. The secondary outcomes were postoperative adverse effects, the
intensity of the postoperative pain and the number of patients who
needed additional analgesic. The postoperative adverse effects and
the number of patients who needed additional analgesic were
presented as percentage frequencies and tested by chi-square test.
VAS pain score was repeated variables and tested by repeated
measures within groups and ANOVA. P < 0.05 was considered
statistically signiﬁcant. Sample size was calculated by preliminary
experiment with a ¼ 0.05 and b ¼ 0.10, 37 patients were needed in
each group. Considering the sample size calculation and the
withdraw person, we chose 40 patients in each group. The datawas
analyzed by SPSS software, version 21.0.3. Results
This study included 120 patients, 7 patients were excluded
eventually. The excluding reasons are described as follow: drain
tube was installed after surgery in 6 patients; the LC was switched
Table 3
Postoperative outcome of the three groups (mean  SD) and n(%).
Variable Group A
(n ¼ 37)
Group B
(n ¼ 38)
Group C
(n ¼ 38)
Mean PACU LOS (min) 32.4  7.2* 39.1  10.4** 42.2  7.6
Mean discharge time (min) 148.4  39.3* 187.9  47.7** 223.4  52.5***
Additional analgesics
need, n (%)
7 (19%)* 13 (34%) 18 (47%)
Postoperative agitation, n (%) 0* 7 (18%) 9 (24%)
Backache, n (%) 3 (8%)* 11 (29%)** 12 (32%)
Nausea, n (%) 9 (24%) 13 (34%) 14 (37%)
Vomiting, n (%) 7 (19%) 9 (24%) 10 (26%)
Dizziness, n (%) 0 5 (13%) 7 (18%)
Somnolence, n (%) 1 (3%) 2 (5%) 6 (16%)
Sore throat, n (%) 1 (3%) 1 (3%) 2 (5%)
Urinary retention, n (%) 0 1 (3%) 2 (5%)
*P< 0.017 Group A and group C have signiﬁcant difference, **P< 0.017 group A and
group B have signiﬁcant difference,***P< 0.017 group B and group C have signiﬁcant
difference.
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tients, there was no signiﬁcant difference in the baseline data
among the three groups (Table 2).
The PACU LOS in the group A was shorter than group B and
group C (mean PACU LOS: 32.4  7.2 min versus 39.1  10.4 min
versus 42.2  7.6 min, P < 0.01), PACU LOS between group B and
group C had no signiﬁcant difference (P¼ 0.08). Times to PADSS> 9
in the group A was the least compared with group B and group C
(mean ambulatory unit LOS: 148.4  39.3 min versus
187.9  47.7 min versus 223.4  52.5 min, P < 0.01), group B also
had shorter ambulatory unit LOS compared with group C (P ¼ 0.01)
(Table 3).
Compared with group B and group C, patients in group A
demonstrated statistically signiﬁcant improved VAS postoperative
(P < 0.05). Group B also had a better improved VAS than group C.
The intensity of pain was most severe in the ﬁrst 0.5e2 h post-
operative (Fig. 1).
Fewer additional analgesics were used to manage pain in the
group A comparedwith group C (P< 0.01). There were 7 patients in
group A (19%) needed additional analgesics, while 13 patients in
group B (34%) and 18 patients in group C (47%). The number of
patients needed additional analgesics was not signiﬁcantly
different between group A and group B (P ¼ 0.13), also between
group B and group C (P ¼ 0.24). There were 2 patients in group B
required twice additional analgesics (the ﬁrst timewas in the PACU,
the second time was in ambulatory unit), while 3 patients in group
C. The additional analgesic dose was about 5.4 ug in group A and
group B, 5.3 ug in group C.
The frequency of emergency agitation was signiﬁcantly
decreased in group A (P < 0.01). No one occurred in group A, but 7
patients occurred in group B (18%) and 9 patients in group C (24%). 3
patients (8%) in group A, 11 patients (29%) in group B and 12 pa-
tients (32%) in group C complained of the backache, but there was
signiﬁcant difference only between group A and group C (P ¼ 0.01).
There was no statistically signiﬁcant difference among three
groups with regard to postoperative nausea, vomiting, dizziness,
somnolence and urinary retention (Fig. 2).
The vital signs, including mean blood pressure (MBP), heart rate
(HR) and SpO2 (arrived at the operation room, 5 min before extu-
bation, at the extubation time, 5 min after extubation) were not
signiﬁcantly different (P > 0.05).
4. Discussion
This study showed that a single dose of parecoxib 40 mg pre-
operative IV was associated with a shorter LOS in the PACU and
earlier to discharge, reduced postoperative additional analgesics
consumption, relieved pain level in the ﬁrst 24 h, less postoperative
side effects and better recovery.
In this study, the main factors that inﬂuenced the PACU LOS
were early postoperative activity, consciousness and pain. TheTable 2
Patient demographics (mean  SD).
Variable Group A
(n ¼ 37)
Group B
(n ¼ 38)
Group C
(n ¼ 38)
Mean age (years) 38  9 41  9 41  12
Weight 59.0  10 59.8  10 59.6  11
Height 160.6  7 162.4  7 162.5  9
Sex (male/female) 12/25 12/26 12/26
ASA I/II 25/12 26/12 25/13
Duration of surgery (min) 43  15 44  13 48  13
Sufentanil (ug) 15  2 15  2 15  2
Remifentanil (ug) 378  166 399  138 412  157
Propfol (mg) 436  159 436  138 441  160inﬂuence of respiration, circulation and oxygen saturation on the
modiﬁed Aldrete’s score had little difference in three groups. The
incidence of postoperative residual paralysis in administrating a
single intubation dose of intermediate-acting muscle relaxants was
as high as 17%e45% [20]. To reduce the incidence of postoperative
residual paralysis, every patient was given neostigmine to antag-
onize the muscle relaxant aiming to reduce the degree of residual
paralysis. The frequency of emergency agitation was signiﬁcantly
decreased in group A compare to group C. There were studies re-
ported the same result with our study that preoperative intrave-
nous parecoxib 40 mg could signiﬁcantly reduce the incidence of
emergency agitation in those patients undergoing general anes-
thesia after LC [21]. The mechanism of agitation after general
anesthesia was still unknown, as we know pain was the most
important element. Patients were injected sufentanil 5e7.5 ug
when VAS > 4 or patients were asking for analgesic. After the
treatment each patient would observe 30 min more to prevent
respiratory depression. Our study revealed fewer additionalFig. 1. VAS (0 ¼ no pain, 10 ¼ worst possible pain) at 0, 0.5, 1, 2, 4, 6, 12, 24 h after
surgery in the three groups. Analyze by the repeated measures within groups, there
are differences among the three group, P < 0.05.
Fig. 2. The postoperative adverse effects among the three groups within 24 h.
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there was no statistic difference between group A and group B.
Therefore group A had a shorter PACU LOS. In our hospital, for se-
curity reasons, we normally used sufentanil instead of morphine to
manage patients’ pain in PACU to reduce drug adverse reactions.
Perhaps, sufentanil, having a short half-life, allows early discharge
from PACU.
The main factors inﬂuenced the PADSS score were pain and ac-
tivity. Just one patient in this study had surgical bleeding and was
cured soon. The reported incidence of PONV after LC may be as
frequently as 70% when no prophylactic antiemetic was provided
[22]. As ondansetron was provided in this study, the incidence of
PONV (24e37%) was lower than that of reported previously, and
there was no difference in PONV among groups. In this study most
patients developed PONV during the 24 h after discharge and it was
not very serious. The main reasons affected the early activity were
psychological factors and patient activity limitations, including frail
and pain. We did a good job in comforting and persuading patients
to ease tension preoperatively, make patients recognize the impor-
tance and feasibility of early postoperative activity. Three groups of
patients’ postoperative physical recovery time had obvious differ-
ence and postoperative pain also made some patients difﬁcult to
activity. Comprehensive described above, group A had a shortest
discharge time and group B had a shorter time than group C.
Postoperative pain and PONV are the common complications of
LC. Both of them prolong postoperative recovery time and
discharge time; can even lead to unexpected readmission after
ambulatory surgery. Pain is considered to be the most important
independent predictor associated with postoperative recovery time
and it may also result in PONV. Parecoxib is more andmore popular
in ambulatory surgery because of effective analgesia and less side
effects [23]. There is evidence that preoperative administration of
parecoxib and postoperative continued with oral valdecoxib up to
seven days resulted in a shorter LOS in the PACU, quicker speed of
postoperative recovery, fewer adverse effects of opiods, faster re-
turn to normal activities, improved sleep proﬁle and greater patient
satisfaction [24].
Postoperative pain of LC usually can be divided into three main
parts: incision pain, visceral pain caused by peritoneal irritation(including low back pain) and shoulder pain from the irritation of
the diaphragmatic peritoneum. It was reported that postoperative
pain during the ﬁrst week showed signiﬁcant individual differ-
ence [8]. Successful pain management required rapid onset of
effect and long duration of action analgesic. In this study, we
found the intensity of pain was most severe during the ﬁrst 0.5e
2 h postoperatively. This was approximately the same with the
study reported by Joris J et al. who found the total pain peaked
within 1e4 h after LC [25]. Present study also indicated that
preoperative administration of parecoxib could reduce visceral
pain, and less backache occurred in group A compared with group
B and group C.
Our study has the same results with one research suggested that
preoperative administration of parecoxib was more effective than
postoperative usage on pain relief after surgery in patients under
going elective surgery like hernioplasty, appendicectomy and
cholecystectomy. Both the regimens were well tolerated, but it
appeared that preoperative parecoxib 40 mg was a more useful
option for postoperative pain relief [26]. However another study
reported preoperative administration of parecoxib did not provide
with preemptive analgesia effect after hip arthroplasty. However in
the preoperative group there was a tendency of improving anal-
gesia immediately, this was consistent with the effect of NSAIDs
expected working time. [27] One meta-analysis suggested that
preemptive administration of NSAIDs could reduce postoperative
analgesic consumption and extend the period of additional anal-
gesic, it also suggested that preemptive analgesia had more ad-
vantages than postoperative administration, but it did not reduce
postoperative pain scores [28]. Our study indicated preemptive
analgesia reduced postoperative pain scores and decreased post-
operative analgesic consumption, those may result in a different
postoperative pain management strategy in our study.
The reduced requirement for opioids and relived VAS score may
account for many ﬁndings in the study: group A had a fewer opioids
consumption, shorter LOS in the PACU and earlier to discharge, less
postoperative agitation, fewer other resources were used during
the recovery period.Whether from clinical or economic standpoint,
the length of time spent in the hospital was increasingly important
in ambulatory surgery. LOS is one determinant factor of the total
cost.
Till now LOS is difﬁcult to accurately quantify because it relevant
to multiple variables, including anesthetic technique, pain,
drowsiness, nausea/vomiting and systematic factors [29]. This was
also one of the defects of this experiment, so we chose the clinical
most popularly used evaluation criteria-PADSS scores. The other
defect was the patients’ actual discharge time was not agree with
our assessment standard time, the main reason lied in no family
accompany and the restriction of transportation. The third defect
was we did not using the multimodal analgesia just like local
inﬁltration around the wound to relive pain. The clinical value of
inﬁltration of wounds with local anesthetics (LA) and their intra-
peritoneal application for treating pain after LC still remain
controversial [30e33]. The majority of the randomized trials
demonstrated reduced pain scores in the treatment group. How-
ever therewere also several trials inwhich no reduction of painwas
observed. We wanted to study the local inﬁltration as a separate
factor in the next phase of study, so in this study we didn’t use local
inﬁltration. Moreover this study was not a multi-center study, this
was just a preliminary study in our hospital, we needed multi-
center research to conﬁrm our research.
In conclusion, preoperative administered of parecoxib 40 mg
before LC is associated with a shorter LOS in the PACU and earlier to
discharge, reduced postoperative additional analgesics consump-
tion, relieved pain level in the ﬁrst 24 h and less postoperative
adverse effects.
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